Navigation Links
Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
Date:6/8/2012

BERLIN, June 8, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis (RA). The results were presented as a late-breaking oral presentation at the European League Against Rheumatism's (EULAR) Annual European Congress of Rheumatology [EULAR abstract LB0005: 12-Week Results of a Phase IIb Dose-Ranging Study of LY3009104 (INCB028050), an Oral JAK1/JAK2 Inhibitor, in Combination with Traditional DMARDs in Patients with Rheumatoid Arthritis].

The Phase IIb randomized double-blind, placebo-controlled, dose-ranging study, known as JADA, involved a total of 301 patients with active RA on stable doses of methotrexate. Patients were randomized to receive either placebo or one of four once-daily doses of baricitinib (1 mg, 2 mg, 4 mg or 8 mg) for 12 weeks.

Primary Endpoint Achieved

The Phase IIb trial achieved the primary endpoint by demonstrating a statistically significant difference in the American College of Rheumatology 20 (ACR20) response between the combined 4 mg and 8 mg baricitinib groups (76 percent) compared with placebo (41 percent) after 12 weeks of treatment (p<0.001). Statistically significant improvement was observed at the first assessment point after two weeks of treatment and was sustained through week 12.

Summary of Secondary Endpoints

A statistically significant difference in response for the ACR20, ACR50 and ACR70 secondary endpoints was observed with the 1 mg, 4 mg and 8 mg dose groups compared with placebo.

ACR20

  • 8 mg: 78 percent (p<0.001)
  • 4 mg: 75 percent (p<0.001)
  • 2 mg: 54 percent (
    '/>"/>

SOURCE Eli Lilly and Company; Incyte Corporation
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
2. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
3. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
4. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. DiversityInc Names Lilly a Top Company for Diversity
7. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
8. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
9. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
10. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
11. Life Extension Foundation® study finds Cognitex® with NeuroProtection Complex may provide a positive impact on cognitive performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 Neurocrine Biosciences, Inc. (Nasdaq: ... , President and Chief Executive Officer of Neurocrine Biosciences, will ... dbAccess Health Care Conference in Boston.   The ... a.m. Eastern Time / 8:20 a.m. Pacific Time.  The presentation ... website at http://www.neurocrine.com . If you ...
(Date:5/23/2013)... 23, 2013  Haemonetics Corporation (NYSE: HAE ) ... & EVP-Business Development, will present at The Deutsche Bank 38 ... Boston, MA on May 29, 2013 at 1:30pm ... The public may access Mr. Lindop,s presentation live ... Haemonetics Haemonetics (NYSE: HAE ) is ...
(Date:5/23/2013)... WASHINGTON , May 23, 2013 Hearing health ... active, feel younger, and remain socially and professionally engaged, he ... is the overriding message that the Better Hearing Institute ... support of National Men,s Health Week , which leads ... Health Week runs from June 10 through June 16. ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4
... Hospital (MGH) Cancer Center has purchased four radiation therapy treatment ... and one Elekta Synergy® S. The order, which includes ... facility to offer patients a complete cancer treatment solution from ... systems position MGH to take advantage of Volumetric ...
... 2 The Asthma and Allergy Foundation of America (AAFA) ... annual research project ranks the fall,s 100 most challenging cities ... this year are: McAllen, TX (1); Wichita, KS (2); Louisville, ... In addition, according to a recent AAFA survey, fall ...
Cached Medicine Technology:Massachusetts General Hospital Selects Elekta As New Vendor for Complete Cancer Treatment Solution 2New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 2New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 3New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 4New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 5New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 6
(Date:5/25/2013)... On May 20, 2013 the Sydney Morning Herald ... or plan for their eventual demise, but it is an ... Must-Do List to help people properly arrange for their last ... fact sheet.” , While not a formal document, this document ... It may include a summary of assets, debts, obtained ...
(Date:5/25/2013)... 2013 The latest report from ... bowel syndrome (IBS) to bloating, constipation, diarrhea and ... long-lasting, embarrassing, frustrating and difficult health issues to ... health have provided a cure for these ... contributing to digestive health issues, a healthy diet ...
(Date:5/25/2013)... On May 25, Voices Against Brain ... advocacy, comments on a new study by the Max ... atmospheric plasma into brain cancer treatment may help when ... Science Daily article, physicists from the Max ... demonstrated the “synergistic effect of cold atmospheric plasma -- ...
(Date:5/25/2013)... 25, 2013 Many orthodontists have thought ... where exactly that cloud is. Most people would ... with to provide their cloud service and support would ... the service they're selling, they'd be wrong. Cloud ... (a secure, redundant facility that houses servers and related ...
(Date:5/25/2013)... According to world-renowned scholars, Queen Cleopatra VII was ... ever lived. Cleopatra’s legendary beauty moved nations and her ... men in her time. Cleopatra was also a scientist ... glowing and fresh, from her legendary milk baths to ... cyprus grass. , Cleopatra was said to possess the ...
Breaking Medicine News(10 mins):Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:Cirrus Ortho Launches Cloud Computing for Orthodontic Industry That is Unlike Any Other 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3
... cancer treatments using their knowledge about an obesity drug, orlistat ... in the laboratory . ,The drug binds and ... the protein's function and causes cell death. ,The ... Kridel and W. Todd Lowther at Wake Forest University School ...
... serve to repress an alcoholic's desire for drink, according ... of California-San Francisco . ,Varenicline, manufactured by ... the United States and Europe in 2006, has been ... reward system for addictive substances. ,The research ...
... that a large number of Internet searches are health ... the healthcare sector . This, claims Cambridge UK based ... and medical device manufacturers. According to a series of ... having to come to terms with informed patients who ...
... into a skin-care product that would wipe away wrinkles and ... ,The government's team of camel researchers, which has already pioneered ... found cosmetic properties in the hardy mammal's milk. ... a hospital's skin department to study it on 20 people ...
... or kill tumors in the pancreas of mice, US researchers ... of the deadliest human cancers ,The mutant gene ... kill themselves, researchers from The University of Texas MD Anderson ... more lethal mutant, called BikDD, which spares healthy tissue. ...
...
Cached Medicine News:Health News:Battle Between Google and Microsoft Could Trigger Revolution in Healthcare 2Health News:Mutated Gene Zaps Pancreas Cancer in Mice 2
... the parafollicular C-cells of the thyroid gland ... major action of calcitonin is to lower ... resulting in decreased mobilization of calcium from ... in conditions associated with high levels of ...
Calcitonin RIA Kit...
Validated by decades of research and clinical experience, HFA is the accepted standard of care in glaucoma diagnosis and management. With HFA you can feel confident you're providing the best possible...
... been a standard requirement for ... during laser procedures, however, many ... that smoke plume generated from ... as smoke plume generated from ...
Medicine Products: